News of the week: AI in the clinic, a PBM fight, and a customs rule on pause

< 5 min read

Share

A folded felt newspaper.

Four stories from the week ending October 18, 2026, for anyone who fills a prescription.

The short answer: clinicians are using AI for treatment questions at large scale, the AMA says AI should earn clinical authority with evidence, states keep moving to separate PBMs from the pharmacies they own, and a customs rule that could have disrupted prescriptions mailed from abroad is delayed to January 20, 2027.

A prescription passes through more hands than the one that signs it: the tools a clinician consults, the middlemen who set the price, and now and then a customs officer. This week, news touched almost all of them.

How doctors use AI: the first big numbers

In the first large-scale study of clinicians' AI use, published in JAMA on October 15, researchers at Harvard Medical School and Brigham and Women's Hospital analyzed OpenEvidence, an AI clinical information platform. From January 2024 through June 2026, 952,008 US clinicians, including 556,200 physicians, submitted 271 million queries. In a classified sample of 38.8 million queries, 51.9% concerned clinical decision-making, mostly treatment and management (33.1%); diagnosis was 13.9%. Harvard Medical School's write-up notes that three co-authors are OpenEvidence employees and that the company supplied the data but did not fund the study. It measured use, not whether answers were accurate or patients did better.

Why it matters: the clinician deciding on your prescription may be consulting an AI tool, and this study did not test whether that improves care.

The AMA's rules of the road for clinical AI

The American Medical Association published a governance framework on October 13 for agentic AI that takes on clinical functions. Its governing principle: "clinical authority should be earned through evidence and maintained through demonstrated performance." It poses four questions: what function the AI performs, what shows it can do that and what happens if it fails, what it should be permitted to do and under what oversight, and who is accountable. The one-page PDF goes further than the web page, listing example functions from "document" and "triage" to "diagnose," "treat," and "prescribe," and a scope ladder: "Inform → recommend → decide → act." It guides the AMA's policy work; it is not a regulation.

Why it matters: if AI ever writes or renews your prescription, the AMA wants it to prove itself first, with someone clearly accountable.

Both parties take aim at PBMs

WPLN, in a partnership with NPR and KFF Health News, reported on October 16 that pharmacy benefit managers have become a bipartisan target. Every state has imposed some restrictions on PBMs, and Tennessee is among a growing number moving to bar companies that own PBMs from also owning pharmacies, as CVS does. Tennessee's FAIR Rx Act was signed May 27, 2026; WPLN says the ownership ban takes effect in 2028. CVS fought it with a $7 million TV ad campaign claiming it would have to close all 134 of its Tennessee pharmacies, and has sued. A legislative analysis found the bill could raise costs in the short term. The PBM trade group says PBMs are the only part of the supply chain working to lower drug costs.

Why it matters: the story's own example is a Tennessee man who, paying cash at his local pharmacy, got a 90-day supply of his blood pressure medicine for what 30 days cost through his CVS Caremark plan. The cash price is worth asking about.

A customs rule for mailed medicine is delayed

U.S. Customs and Border Protection announced on October 14 that mandatory use of Entry Type 13, a new electronic filing for international mail, moves from October 22, 2026 to January 20, 2027, a 90-day extension to give filers "more time" to adjust to the new electronic requirements. It will cover postal shipments subject to Section 201, 232, or 301 duties or under a Partner Government Agency's jurisdiction. CBP's release does not mention prescriptions. STAT reported that the rule could prevent Americans from obtaining prescription drugs from licensed international pharmacies, and that patient groups and dozens of lawmakers had urged a rethink.

Why it matters: if you order medicine by mail from abroad, CBP says procedures stay the same until January 20, but the rule is delayed, not withdrawn.

Where Temi fits

Temi's fees are cash-pay and Temi never bills insurance; if a physician approves your refill, you pick the pharmacy and pay it for the medication, with insurance or a discount card if you have one.

Sources

Editorial Standards

This article has not been reviewed by a licensed physician. We cite peer-reviewed studies, academic research institutions, and medical associations. Our sources are listed at the end of each article.

If you notice an error or have a concern about our content, please email supportusetemi.com.

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for diagnosis and treatment.

Felt Temigami re-enacting famous revolutions, from crossing the Delaware to raising a pill-bottle flag.

The revolution will be emailed.

Once a week, roughly. We're taking the fight to a corrupt and broken health insurance system. Join up.

Get Temi's newsletter by email. Unsubscribe anytime. Privacy policy

Temi

Start online, and a licensed physician reviews your request

See if you qualify

A licensed physician reviews every request. Nothing on this page is a prescription.